Novartis turns to algorithms developer Anumana to apply AI to cardio conditions
Related Articles
Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease
Diagnostic and Interventional Cardiology: Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosisDecember 20, 2022
Researchers use AI to detect weak heart pump via patients’ Apple Watch ECGs
Medical Xpress: Single-lead ECG tracings from an Apple Watch interpreted by an artificial intelligence (AI) algorithm developed at Mayo Clinic effectively identified patients with a weak heart pump. To interpret…May 01, 2022
Anumana, Inc. announced that it has received funding from Boston Scientific Corporation, Matrix Capital Management, Mayo Clinic, Endowment Arm, Matrix Management Corporation, NTT Venture Capital
MarketScreener: Anumana, Inc. announced that it has received a round of funding from new investor, Boston Scientific Corporation on April 24, 2025. The transaction included participation from returning investors, Matrix…April 24, 2025
Anumana wins FDA breakthrough status for AI algorithm to detect PH
NS Medical Devices: AI-driven health technology company Anumana has received breakthrough device designation from the US Food & Drug Administration (FDA) for its ECG-based Pulmonary Hypertension (PH) algorithm. The AI-enhanced…May 24, 2022